Physician profile
Patrick D Walker
NPI 1245441658
$15,325.41
in general payments reported to CMS, 2019-2025
49 companies · $2,198 in 2025
The $2,198 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,291 · 2020: $1,919 · 2021: $2,505 · 2022: $2,270 · 2023: $2,266 · 2024: $1,875 · 2025: $2,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,265 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,264.81 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,850.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,372.31 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $1,345.49 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,339.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,330.99 | 2019-2025 | |
| Novo Nordisk INC | $1,074.05 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $1,044.35 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $698.41 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $675.13 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $550.72 | 2019-2024 | Xarelto, Spravato |
| Sanofi-Aventis U.S. LLC | $338.92 | 2019-2025 | |
| Amgen INC. | $281.26 | 2019-2025 | Repatha, Repatha, Otezla |
| Allergan, INC. | $264.50 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250.48 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $247.58 | 2019-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.